1 not yet recruiting, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Pediatric ALL, B Cell: new trials by email Literature Review of Pediatric ALL, B Cell trials Research Report on Pediatric ALL, B Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) Blinatumomab for Injection - Pediatric ALL, B Cell, Minimal Residual Disease | Phase 1 | Unknown | Seoul National University Hospital | 20 | 2022-02-18 | 2022-03-08 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Leukemia, Myeloid, Acute (1) · Neoplasm, Residual (1) · Neoplasms (1) · Recurrence (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1)
Azacitidine (1) · Dexamethasone (1) · Injections (1) · Inotuzumab Ozogamicin (1) · blinatumomab (1)
BeOne Medicines (1) · Seoul National University Hospital (1)
South Korea (1)